2016
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial
Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DL, Investigators C. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. The American Journal Of Medicine 2016, 129: 1002-1005. PMID: 27143321, DOI: 10.1016/j.amjmed.2016.03.042.Peer-Reviewed Original ResearchConceptsDual antiplatelet therapyProton pump inhibitorsAcute coronary syndromePercutaneous coronary interventionCardiovascular eventsCoronary syndromeCoronary interventionGastrointestinal eventsPercutaneous coronary intervention-treated patientsSafety of PPIsUnadjusted Cox proportional hazards modelCox proportional hazards modelDays of randomizationMajor cardiovascular eventsComposite cardiovascular eventsSubset of patientsSafety of omeprazoleProportional hazards modelGastroprotective strategiesMedian followPPI therapyAntiplatelet therapyFrequent indicationHazards modelPatientsProton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy
Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP, Investigators C. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. Journal Of The American College Of Cardiology 2016, 67: 1661-1671. PMID: 27012778, DOI: 10.1016/j.jacc.2015.12.068.Peer-Reviewed Original ResearchMeSH KeywordsAgedAspirinClopidogrelDose-Response Relationship, DrugDrug Therapy, CombinationDyspepsiaFemaleGastrointestinal HemorrhageHumansIntestinal ObstructionIntestinal PerforationMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationOmeprazolePainPeptic UlcerPlatelet Aggregation InhibitorsProspective StudiesProton Pump InhibitorsStrokeTiclopidineConceptsDual antiplatelet therapyLow-dose aspirinProton pump inhibitorsMajor adverse cardiac eventsAdverse cardiac eventsPPI therapyAntiplatelet therapyAspirin usersGastrointestinal eventsCardiac eventsGI eventsMeier estimatesArtery diseaseCardiovascular endpointsLow-dose aspirin usersPrimary cardiovascular endpointUpper GI eventsHigh-dose aspirinPeripheral artery diseasePercutaneous coronary interventionCoronary artery diseaseHigh rateAspirin groupBlinded gastroenterologistsAspirin dose
2010
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal Of Medicine 2010, 363: 1909-1917. PMID: 20925534, DOI: 10.1056/nejmoa1007964.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsDual antiplatelet therapyUpper gastrointestinal bleedingAntiplatelet therapyCardiovascular eventsGastrointestinal bleedingOvert upper gastrointestinal bleedingPrimary cardiovascular end pointEnd pointEvent ratesEfficacy of clopidogrelSymptomatic gastroduodenal ulcersCardiovascular end pointsComposite of deathNonfatal myocardial infarctionSerious adverse eventsCoronary artery diseaseHigh-risk subgroupsRisk of diarrheaCardiovascular causesGastrointestinal complicationsGastrointestinal eventsOccult bleedingAntithrombotic therapyAdverse events
2008
Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac
Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP. Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac. Gastroenterology 2008, 135: 1517-1525. PMID: 18823986, DOI: 10.1053/j.gastro.2008.07.067.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalConfidence IntervalsCyclooxygenase InhibitorsDiclofenacDose-Response Relationship, DrugEtoricoxibFemaleFollow-Up StudiesGastrointestinal HemorrhageHumansIncidenceMaleMiddle AgedOdds RatioOsteoarthritisProspective StudiesPyridinesRisk FactorsSulfonesTreatment OutcomeConceptsLower GI eventsClinical eventsGI eventsRisk factorsCOX-2 selective inhibitorsBlinded adjudication committeeLower Gastrointestinal EventsTraditional NSAID diclofenacUpper GI eventsDouble-blind trialSignificant risk factorsMajor risk factorAnti-inflammatory drugsSelective inhibitorNonsteroidal anti-inflammatory drug diclofenacGastrointestinal eventsNSAID useProspective trialMultivariable analysisRheumatoid arthritisAdjudication committeeMean durationCyclo-oxygenaseNSAID diclofenacAbstractText
2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, Committee F. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. The Lancet 2007, 369: 465-473. PMID: 17292766, DOI: 10.1016/s0140-6736(07)60234-7.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalArthritisArthritis, RheumatoidAspirinCyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDiclofenacEtoricoxibFemaleGastrointestinal DiseasesGastrointestinal HemorrhageHumansMaleMiddle AgedOsteoarthritisPeptic UlcerPlatelet Aggregation InhibitorsProton Pump InhibitorsPyridinesSulfonesConceptsProton pump inhibitorsNon-steroidal anti-inflammatory drugsUpper gastrointestinal safetyLow-dose aspirinClinical eventsGastrointestinal safetyRheumatoid arthritisUncomplicated eventsTraditional non-steroidal anti-inflammatory drugsConcomitant proton pump inhibitorsLow-dose aspirin useCOX-2 selective inhibitorsTraditional NSAID diclofenacAnti-inflammatory drugsStandard clinical practiceSelective inhibitorGastrointestinal eventsMultinational EtoricoxibAspirin useGastrointestinal outcomesTreat analysisProtective therapyPump inhibitorsCyclo-oxygenaseNSAID diclofenac
2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, Committee F. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. The Lancet 2006, 368: 1771-1781. PMID: 17113426, DOI: 10.1016/s0140-6736(06)69666-9.Peer-Reviewed Original ResearchConceptsThrombotic cardiovascular eventsNon-steroidal anti-inflammatory drugsCardiovascular eventsHazard ratioRheumatoid arthritisCyclo-oxygenase-2 (COX-2) selective inhibitorsTraditional non-steroidal anti-inflammatory drugsCOX-2 selective inhibitorsPrespecified pooled analysisRelative cardiovascular riskTraditional NSAID diclofenacUpper gastrointestinal eventsPlacebo-controlled trialAverage treatment durationAnti-inflammatory drugsSelective inhibitorLong-term useDiclofenac groupEtoricoxib groupGastrointestinal eventsMultinational EtoricoxibCardiovascular outcomesCardiovascular riskTreat analysisClinical events
2004
Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy
Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy. Alimentary Pharmacology & Therapeutics 2004, 19: 197-208. PMID: 14723611, DOI: 10.1111/j.0269-2813.2004.01834.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProton pump inhibitorsCost of NSAIDsPump inhibitorsGastrointestinal eventsChronic anti-inflammatory therapyRAND/UCLA Appropriateness MethodNon-steroidal anti-inflammatory drugsAnti-inflammatory therapyAnti-inflammatory drugsDrug treatment strategiesCommunity-based settingsCardiovascular riskProphylactic useAppropriateness MethodTreatment strategiesLower riskNSAIDsPatientsClinical scenariosAspirinAppropriate useInhibitorsRiskCare entitiesLiterature review
2003
Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company.
Laine L, Wogen J, Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company. Gastroenterology 2003, 125: 389-395. PMID: 12891540, DOI: 10.1016/s0016-5085(03)00900-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Inflammatory Agents, Non-SteroidalCohort StudiesCost-Benefit AnalysisCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsFemaleGastrointestinal DiseasesHealth ResourcesHumansIsoenzymesLongitudinal StudiesMaleMembrane ProteinsMiddle AgedProstaglandin-Endoperoxide SynthasesRetrospective StudiesConceptsChronic NSAID therapyCoxib therapyNSAID therapyChronic nonsteroidal anti-inflammatory drug (NSAID) therapyNonsteroidal anti-inflammatory drug therapyAnti-inflammatory drug therapyHealth care resource utilizationCOX-2-specific inhibitorsU.S. administrative claims databaseMedco Health SolutionsProportion of patientsAdministrative claims databaseGastrointestinal eventsNewer coxibsInitial prescriptionChronic useClaims databaseDrug therapyClinical trialsDrug costsNew NSAIDClinical practicePatientsTherapyAbstractText
2001
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120: 594-606. PMID: 11179238, DOI: 10.1053/gast.2001.21907.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsGI eventsGI diseasePrevention of NSAIDAnti-inflammatory drug useClinical upper GI eventsHistory of ulcerUpper GI eventsHalf of patientsHigh-risk patientsAnti-inflammatory drugsGastrointestinal eventsNSAID doseGastroduodenal injuryNSAID usersClinical featuresGastric erosionsSteroid useCommon causeDrug usePatientsUlcersDiseaseRiskUnited States today
2000
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M, Hawkey C, Hochberg M, Kvien T, Schnitzer T. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. New England Journal Of Medicine 2000, 343: 1520-1528. PMID: 11087881, DOI: 10.1056/nejm200011233432103.Peer-Reviewed Original ResearchMeSH KeywordsAdultArthritis, RheumatoidCardiovascular DiseasesCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDuodenal ObstructionFemaleGastric Outlet ObstructionGastrointestinal DiseasesGastrointestinal HemorrhageHumansIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedNaproxenPeptic UlcerProportional Hazards ModelsProstaglandin-Endoperoxide SynthasesSulfonesConceptsUpper gastrointestinal eventsNonselective nonsteroidal antiinflammatory drugsGastrointestinal eventsRheumatoid arthritisCyclooxygenase-2Upper gastrointestinal toxicityPercent of patientsPrimary end pointOverall mortality rateNonsteroidal antiinflammatory drugsRate of deathYears of ageNonselective NSAID naproxenSelective inhibitorCardiovascular causesRofecoxib groupGastrointestinal toxicityNaproxen groupMyocardial infarctionSimilar efficacyAntiinflammatory drugsLower incidenceArthritisMortality ratePatients